Ever since weight-loss drugs such as Novo Nordisk’s Ozempic were introduced to India last year, Reema Arora, a doctor who runs an aesthetics clinic in New Delhi, has seen a 30 per cent jump in patients seeking treatments to slim down.
After last month’s expiry of Indian exclusivity on the patent for semaglutide, the active ingredient in Ozempic and Wegovy, she expects even greater demand as the world’s largest producer of generic medicines also becomes a big consumer of weight-loss drugs.
“It’s going to be a paradigm shift,” said Arora, founder of The Face Clinic. “Generics are definitely going to help us with penetration into areas which, because of the cost or the availability, people didn’t have access. It’s going to be hugely impacting.”
您已阅读12%（749字），剩余88%（5688字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。